Insulin Icodec, Recombinant

Modality

Proteins
Nucleic Acids
Animal Biologics
Vaccines
Aesthetic Medicines
Diagnostic Reagents
Raw Materials and Reagents

Insulin Icodec, Recombinant

Description Of Insulin Icodec, Recombinant

Insulin Icodec is chemically named LysB29(icosanedioic acid) A14E, B16H, B25H, desB30 human insulin analog. It is a long-acting basal human insulin given subcutaneously once a week.

Insulin icodec was developed by Novo Nordisk, and approved in 2024, under the brand name Awiqli, for glycemic control in diabetes mellitus patients.

Synonyms

Awiqli, IA287, Insulin Icodec, CAS 1188379-43-2

Amino Acid Sequence of Insulin Icodec

Expression System of Insulin Icodec

Brand Name	Active Substance	Expression System
Awiqli	Insulin Icodec	Yeast (Saccharomyces cerevisiae)

Formulation of Insulin Icodec

Inactive ingredients (Excipients) in Awiqli (Prefilled Cartridge)

Glycerol, metacresol, phenol, sodium chloride, water for injection and zinc acetate.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Insulin

Microbial Strain Engineering and Screening
Microbial Cell Banking (PCB/MCB/WCB)
Upstream Process Development
Downstream Process Development
Formulation Development
GMP Manufacturing
Fill and Finish
Analytical and Testing
Regulatory Affairs

All Categories

Insulin Icodec, Recombinant

Modality